Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Tizanidine

A centrally acting muscle relaxant and alpha-2 adrenergic agonist that reduces muscle spasticity caused by multiple sclerosis, spinal cord injury or cerebral palsy. Its synthesis was first published in 1974, and it has been approved in the United States since 1996. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards, nitrosamines and other impurities.

Did you know?It is a close chemical relative of clonidine, a blood pressure medicine: both act on alpha-2 receptors, but tizanidine is at least ten times weaker at lowering blood pressure.

TizanidineGo to the active ingredient →
TizanidineActive ingredientTizanidineCat. No. P-T138-001CAS 51322-75-9

EDQM standards 2

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.